Lessons Learned From a Patient-Centered, Team-Based Intervention for Patients With Type 2 Diabetes at High Cardiovascular Risk: Year 1 Results From the CINEMA Program.
Ian J. Neeland,Sadeer G. Al‐Kindi,Nour Tashtish,Elke Eaton,Janice Friswold,Sara Rahmani,Khendi T. White‐Solaru,Imran Rashid,Diamond Berg,Mariam Rana,Claire Sullivan,Betul Hatipoglu,Peter Pronovost,Sanjay Rajagopalan
DOI: https://doi.org/10.1161/JAHA.120.024482
IF: 6.106
2022-07-30
Journal of the American Heart Association
Abstract:Background The care for patients with type 2 diabetes necessitates a multidisciplinary team approach to reduce cardiovascular risk, but implementation of effective integrated strategies has been limited. Methods and Results We conceptualized and initiated a patient‐centered, team‐based intervention called Center for Integrated and Novel Approaches in Vascular‐Metabolic Disease (CINEMA) at University Hospitals Cleveland Medical Center. Patients with type 2 diabetes at high risk for cardiovascular events, including those with established atherosclerotic cardiovascular disease, elevated coronary artery calcium score >100, chronic heart failure with reduced ejection fraction, and/or chronic kidney disease stages 2 to 4 were included. Herein, we present the year 1 results for the program. From May 2020 through August 2021, there were 417 referrals. Among 206 eligible patients, 113 (55%) completed a baseline and ≥1 follow‐up visit through December 2021, with mean (SD) time of 105 (34) days between baseline and first follow‐up visits. Mean age was 59 years, with 49% women and 37% Black patients. Patients had significant reductions from baseline in glycosylated hemoglobin (−10.8%), total cholesterol (−7.9%), low‐density lipoprotein cholesterol (−13.5%), systolic blood pressure (−4.0%), and body mass index (−2.7%) ( P ≤0.001 for all). In addition, among the 129 (63%) eligible patients not on sodium‐glucose cotransporter 2 inhibitor or glucagon‐like peptide‐1 receptor agonist at baseline, 81% were prescribed evidence‐based therapy with sodium‐glucose cotransporter 2 inhibitor (n=66 [51%]) and/or glucagon‐like peptide‐1 receptor agonist (n=67 [52%]) to reduce the risk of cardiovascular disease in the initial 3‐month follow‐up period. Conclusions A team‐based, patient‐centered approach to high‐risk disease management appears to be a promising paradigm for care delivery associated with greater use of evidence‐based therapies and improved control of multiple cardiovascular risk factors. Nonstandard Abbreviations and Acronyms CDCES certified diabetes care and education specialist GLP‐1 RA glucagon‐like peptide‐1 receptor agonist SGLT2i sodium‐glucose cotransporter 2 inhibitor T2D type 2 diabetes Clinical Perspective What Is New? The care for patients with type 2 diabetes necessitates a multidisciplinary team approach. We designed and implemented an integrated, patient‐centered, team‐based intervention for patients with type 2 diabetes at high risk for cardiovascular disease events, called Center for Integrated and Novel Approaches in Vascular‐Metabolic Disease (CINEMA). In the first year, we found that the program was associated with improved use of evidence‐based therapies (doubling of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist prescription rates) and improved control of cardiovascular risk factors, including glycosylated hemoglobin, blood cholesterol, and body weight; and risk factor improvements generally continued with longer duration of program participation and were seen even among patients under the care of an endocrinologist. What Are the Clinical Implications? Lessons learned will empower a greater number of cardiovascular specialists to address the implementation gap between the evidence and use for patients with type 2 diabetes at high risk for cardiovascular events in a centralized, specialized manner. The CINEMA program, and those like it, will continue to evolve and adapt to the changing landscape of medicine and society by leveraging new technology and refocusing on the value perceived by the patient, rather than by the physician. An integrated, team‐based, patient‐centered approach to high‐risk disease management seems to be a promising paradigm for care delivery in the foreseeable future. The care for patients with type 2 diabetes (T2D) necessitates a multidisciplinary team approach, requiring a high degree of engagement, education, and collaboration. The multiorgan involvement and complexities of treatment (including injectable medications) result in -Abstract Truncated-
cardiac & cardiovascular systems